330 related articles for article (PubMed ID: 11904521)
1. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade.
Tschöpe C; Schultheiss HP; Walther T
J Cardiovasc Pharmacol; 2002 Apr; 39(4):478-87. PubMed ID: 11904521
[TBL] [Abstract][Full Text] [Related]
2. Molecular interactions of vasoactive systems in cardiovascular damage.
Bader M
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S7-9. PubMed ID: 11811382
[TBL] [Abstract][Full Text] [Related]
3. Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems.
Su JB
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):319-28. PubMed ID: 23386283
[TBL] [Abstract][Full Text] [Related]
4. Kinin-related effects of angiotensin-converting enzyme inhibition.
Bönner G
Clin Physiol Biochem; 1990; 8 Suppl 1():6-15. PubMed ID: 2257722
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin and the kallikrein-kinin systems.
Campbell DJ
Int J Biochem Cell Biol; 2003 Jun; 35(6):784-91. PubMed ID: 12676165
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
Liu YH; Yang XP; Sharov VG; Nass O; Sabbah HN; Peterson E; Carretero OA
J Clin Invest; 1997 Apr; 99(8):1926-35. PubMed ID: 9109437
[TBL] [Abstract][Full Text] [Related]
7. Critical insights into the beneficial and protective actions of the kallikrein-kinin system.
Regoli D; Gobeil F
Vascul Pharmacol; 2015 Jan; 64():1-10. PubMed ID: 25579779
[TBL] [Abstract][Full Text] [Related]
8. Impact of kinins in the treatment of cardiovascular diseases.
Regoli D; Plante GE; Gobeil F
Pharmacol Ther; 2012 Jul; 135(1):94-111. PubMed ID: 22537664
[TBL] [Abstract][Full Text] [Related]
9. The kallikrein-kinin system as a regulator of cardiovascular and renal function.
Rhaleb NE; Yang XP; Carretero OA
Compr Physiol; 2011 Apr; 1(2):971-93. PubMed ID: 23737209
[TBL] [Abstract][Full Text] [Related]
10. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors.
Linz W; Schölkens BA
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S83-90. PubMed ID: 1282635
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists.
Sharma JN; Al-Sherif GJ
ScientificWorldJournal; 2006 Oct; 6():1247-61. PubMed ID: 17041716
[TBL] [Abstract][Full Text] [Related]
12. Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.
Lezama-Martinez D; Flores-Monroy J; Fonseca-Coronado S; Hernandez-Campos ME; Valencia-Hernandez I; Martinez-Aguilar L
J Cardiovasc Pharmacol; 2018 Dec; 72(6):291-295. PubMed ID: 30422889
[TBL] [Abstract][Full Text] [Related]
13. Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.
Vora JP; Oyama TT; Thompson MM; Anderson S
Diabetes; 1997 Jan; 46(1):107-12. PubMed ID: 8971089
[TBL] [Abstract][Full Text] [Related]
14. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat.
Wollert KC; Studer R; Doerfer K; Schieffer E; Holubarsch C; Just H; Drexler H
Circulation; 1997 Apr; 95(7):1910-7. PubMed ID: 9107180
[TBL] [Abstract][Full Text] [Related]
16. Kinins in the cardiovascular system.
Schölkens BA
Immunopharmacology; 1996 Jun; 33(1-3):209-16. PubMed ID: 8856152
[TBL] [Abstract][Full Text] [Related]
17. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
Huber K; Pachinger O; Pichler M; Klein W
Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
[TBL] [Abstract][Full Text] [Related]
18. Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.
Regoli D; Gobeil F
Can J Physiol Pharmacol; 2017 Oct; 95(10):1117-1124. PubMed ID: 28384411
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
20. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature.
Tsuchida S; Miyazaki Y; Matsusaka T; Hunley TE; Inagami T; Fogo A; Ichikawa I
Kidney Int; 1999 Aug; 56(2):509-16. PubMed ID: 10432390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
